2025-07-21 マウントサイナイ医療システム(MSHS)
<関連情報>
- https://www.mountsinai.org/about/newsroom/2025/mount-sinai-researchers-engineer-rare-immune-cells-to-create-powerful-new-cancer-vaccine
- https://aacrjournals.org/cancerimmunolres/article-abstract/doi/10.1158/2326-6066.CIR-25-0034/763411/Harnessing-Notch-Signaling-to-Enhance-the?redirectedFrom=fulltext
がん免疫療法に応用するためのヒトI型樹状細胞の生成と機能性を強化するためのノッチシグナルの利用 Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type I Dendritic Cells for Cancer Immunotherapy Applications
Sreekumar Balan;Liam O’Brien;Ante Peros;Xuedi Wang;Ingrid Leal-Rojas;Christopher Mcclain;Kristen J. Radford;Nina Bhardwaj
Cancer Immunology Research Published:July 02 2025
DOI:https://doi.org/10.1158/2326-6066.CIR-25-0034
Abstract
Dendritic cell (DC) based-vaccines remain the sole approved cancer vaccine. Despite their established safety and efficacy in numerous trials against cancers and infections, long-term clinical benefits have been modest. Most trials have employed DCs derived from blood monocytes (MoDC), but emerging evidence underscores the unique role of cDC1 in triggering potent antitumor immune responses and their intratumoral infiltration with favorable prognoses in many cancers. However, the scarcity of cDC1 in peripheral blood and the challenges in generating them in vitro have hindered a deeper understanding of their biology and their widespread application as cellular vaccines. Here, we present a novel serum-free culture system capable of generating billions of human cDC1s from CD34+ progenitors derived from cord or peripheral blood. The system leverages the requirement of Notch signaling for cDC1 differentiation and generates DCs that closely resemble in vivo cDC1s, exhibiting superior functions, including cellular antigen cross-presentation. This robust protocol enables the scalable production of cDC1s for both fundamental biological research and therapeutic applications.
